Complement Therapy for COVID-19

The world-leading-CRO Creative Biolabs has a well-known reputation for its professionalism in development services of complement therapy. To defeat flood-spreading COVID-19 epidemic, we are innovatively putting an eye on the potential of complement therapy.

Inflammatory Factor Storm and SARS-CoV-2

Excessive immune response will lead to the pathogenesis of SARS-CoV-2 and lethality of COVID-19. The fatal inflammatory reaction and acute respiratory distress syndrome (ARDS) in the patient are likely due to the rapid viral replication of SARS-CoV-2. Inflammatory factor storm plays an important role in ARDS caused by viruses. After the infection of these viruses, the body's immune system responded with the intention of clearing the virus. As a result, the virus induced an uncontrolled excessive response, which was manifested by the imbalance of the immune regulatory network, the lack of negative feedback, and the continuous self-amplification of positive feedback, which lead to a variety of inflammatory factors elevate abnormally, eventually resulting in single or multiple organ damage, functional failure, and death.

Potential of Complement Therapy for COVID-19

At present, there is no specific treatment for clinical reinflammatory factor storms, and non-specific combined treatment measures such as the administration of anti-infective drugs and glucocorticoid adjuvant are mostly used. Finding targets from the complement system is one of the important directions to the treatment of inflammatory factor storm. Complement is an important component of the body's natural immunity. When participating in the body's defense against foreign aggression, it will quickly produce a large number of complement precursor proteins to respond to and detect threats. Therefore, complement is important to eliminate the invasion of foreign antigens and maintain the balance of the body's environment. However, excessive activation of complement can induce inflammation and affect the coagulation and fibrinolysis system, and then cause pathological damage. In the complement system, factor C5a is the strongest factor in the early stage of acute infection and tissue damage and inflammation, and is recognized as a broad-spectrum inflammatory amplifier. In the acute inflammatory reaction, C5a also has an important participant status and is regarded as a central accelerator or a "booster" for inflammation. When C5a binds to its receptors on neutrophils, they can be strongly activated and can move to the source of injury or infection, producing oxygen free radicals and activating enzymes, both of which are considered major contributors to cell and tissue damage.

Fig.1 Targeting complement in SARS-CoV-2-associated lung injury. (Antonio M Risitano and Dimitrios C Mastellos, 2020)

Creative Biolabs’ Solutions in Complement Therapy for COVID-19

The complement system, as an important part of the body's innate immune system, plays an important role in defending against foreign bodies, maintaining the steady state of the internal environment, and protecting the body. Abnormalities in the complement system are closely related to infections, autoimmune system diseases, tumors, and other diseases. For ARDS caused by SARS-CoV-2 infection, the complement system also plays a role. Therefore, the development of related therapies targeting the complement system is also an effective strategy for the treatment of COVD-19. Creative Biolabs owns extensive experience and advanced biotechnologies, and is well prepared to help researchers around the world to develop COVID-19 defeating complement therapy in following aspects:

• Targeting complement activating factor, C1 (C1q, C1r, C1s), MASP, C2, C3, C5, C6
• Targeting complement regulators, C1-INH
• Targeting complement receptors and ligands, C5a, C5aR1, C3a

If you are interested in our service, please feel free to contact us.

Browse SARS-CoV-2 Related Complement System Products

Creative Biolabs now offers a wide range of complement system proteins and antibodies associated with SARS-CoV-2.

Click here >.

Reference

1. Antonio M Risitano, Dimitrios C Mastellos, et al. (2020). “Complement as a Target in COVID-19?” Nat Rev Immunol. Jun;20(6):343-344.

For Research Use Only. We do not provide direct services or products for patients.